Stockreport

Climb Bio Reports Third Quarter 2024 Financial Results and Business Highlights

Climb Bio, Inc.  (CLYM) 
PDF Appointed Douglas Williams, Ph.D. as Chair of the Board of Directors FDA Clearance of Investigational New Drug Application (IND) for systemic lupus erythematosus (S [Read more]